PLUS THERAPEUTICS
Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in developing and commercializing stem and regenerative cell therapies for treating cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. The company's research and development efforts are developing novel formulations and delivery methods for existing drugs to improve t... heir efficacy and reduce side effects. Plus Therapeutics utilizes its proprietary nanotechnology platform to enhance the therapeutic potential of drugs, allowing for targeted delivery to tumors while minimizing damage to healthy tissues. Their pipeline includes potential treatments for various types of cancer, including brain cancer and pancreatic cancer. Plus Therapeutics' pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.
PLUS THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.plustherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
737.255.7194
Total Funding:
152.25 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Google Font API WordPress Google Analytics Content Delivery Network Mobile Non Scaleable Content Organization Schema
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
Marc Hedrick President and CEO @ Plus Therapeutics
President and CEO
John Fraser Chief Scientist @ Plus Therapeutics
Chief Scientist
2001-01-01
John Ferris Senior Director - European Business Development @ Plus Therapeutics
Senior Director - European Business Development
2006-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-02-15 | Azaya Therapeutics | Azaya Therapeutics acquired by Plus Therapeutics | N/A |
Investors List
AIGH Capital Management
AIGH Capital Management investment in Post-IPO Equity - Plus Therapeutics
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Plus Therapeutics
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Plus Therapeutics
GE Capital
GE Capital investment in Post-IPO Debt - Plus Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Plus Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Plus Therapeutics
Official Site Inspections
http://www.plustherapeutics.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.61 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Plus Therapeutics"
About Us - Plus Therapeutics (PSTV)
We envision innovative radiotherapeutics that become a global standard of care for cancer. Plus Therapeutics (PSTV on Nasdaq) is a U.S. clinical-stage pharmaceutical company, backed by …See details»
Our Team - Plus Therapeutics (PSTV)
No matter our role, our employees share equal dedication to solving the most difficult challenges in cancer treatment through novel radiotherapeutics.See details»
Plus Therapeutics - Wikipedia
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. The company is headquartered in Austin, Texas, United States. See details»
Plus Therapeutics, Inc. | LinkedIn
Plus Therapeutics (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers ...See details»
Plus Therapeutics (PSTV) Company Profile & Description
Mar 18, 2025 Company profile for Plus Therapeutics, Inc. (PSTV) stock, with a description, list of executives, contact details and other key facts.See details»
Plus Therapeutics - Crunchbase Company Profile
Plus Therapeutics is a clinical-stage pharmaceutical company that develops targeted therapies to treat cancer and other serious diseases.See details»
Plus Therapeutics - Overview, News & Similar companies - ZoomInfo
May 17, 2024 View Plus Therapeutics (www.plustherapeutics.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Plus Therapeutics Significantly Expands Investigational Oncology …
Jan 6, 2022 The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186 RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma …See details»
Pipeline - Plus Therapeutics (PSTV)
A promising suite of precision radiotherapeutics. Leveraging novel drug formulations, we have developed a radiotherapeutic platform with the potential to lengthen and improve the lives of …See details»
Plus Therapeutics Announces New Employment Inducement
Mar 5, 2025 Plus Therapeutics Announces New Employment Inducement Grants March 05, 2025 16:01 ET | Source: Plus Therapeutics Inc.Plus Therapeutics Announces New …See details»
Plus Therapeutics Announces New Employment Inducement …
HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted …See details»
Plus Therapeutics Reports Third Quarter 2024 Financial Results and ...
AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted …See details»
Plus Therapeutics Expands Management Team and Reports $3.3M …
Jun 7, 2024 Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development programSee details»
About Radiotherapeutics - Plus Therapeutics (PSTV)
In recent years, radiotherapeutics have been developed as a way to deliver radiation therapy directly and specifically to cancer cells. An explosion of new studies shows the potential of …See details»
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim …
Dec 17, 2024 The data were presented in a session titled “Rhenium (186 Re) Obisbemeda (Rhenium Nanoliposome, 186 RNL) for the Treatment of Leptomeningeal Metastases (LM): …See details»
Release Details - ir.plustherapeutics.com
HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted …See details»
For Patients - Plus Therapeutics (PSTV)
At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers.See details»
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted …
6 days ago Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug CandidateSee details»
Plus Therapeutics Presents Positive Clinical Trial Results at the …
Aug 13, 2024 Plus’ CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard …See details»
Our Platform - Plus Therapeutics (PSTV)
However, with traditional approaches in radiation therapy, safely delivering high radiation doses to a single target region and keeping it there long enough to completely eliminate the tumor has …See details»